Trials / Terminated
TerminatedNCT00977067
A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
A Phase Ia, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0152, an IAP Protein Antagonist, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study consists of two stages. In Stage 1, maximum tolerated dose (MTD) will be determined. In Stage 2, additional patients will be treated at the MTD of GDC-0152.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-0152 | Intravenous escalating dose |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-11-01
- Completion
- 2009-11-01
- First posted
- 2009-09-15
- Last updated
- 2017-06-21
Source: ClinicalTrials.gov record NCT00977067. Inclusion in this directory is not an endorsement.